Voruganti L, Awad A G
Institute of Medical Science, University of Toronto, Toronto, Canada.
Psychopharmacology (Berl). 2004 Jan;171(2):121-32. doi: 10.1007/s00213-003-1648-y. Epub 2003 Nov 27.
Neuroleptic dysphoria (ND) is a subtle and under-recognized side effect of antipsychotic drugs. It is an all-inclusive descriptive phrase that encompasses a variety of unpleasant subjective changes in arousal, mood, thinking and motivation induced by neuroleptic drugs. Understanding this phenomenon has wide ranging clinical and research implications.
The present review examined the themes identified in the original studies from the neuroleptic era in the light of recent findings from neuroimaging research, cumulative experience with second generation antipsychotic drugs, and new concepts such as pleasure responsivity, hedonic regulation and subjective tolerability.
Empirical studies on neuroleptic drugs involving clinical populations treated for schizophrenia, Tourette's disorder and stuttering, studies performed on normal healthy volunteers and selected experimental studies in animals, are reviewed.
Dysphoric responses occur early during treatment and typically manifest as a dislike towards medication (drug aversiveness). Dysphoria persisting over time, may lead to adverse clinical consequences such as treatment non-adherence, substance abuse, poor clinical outcome, increased suicidality and compromised quality of life. Interference with the physiological processes of hedonic capacity by the neuroleptics due to their dopaminergic blocking action in the prefrontal cortex and the shell of nucleus accumbens is the putative mediating mechanism underlying the occurrence of dysphoric responses. Second generation antipsychotic drugs with an atypical receptor blocking profile are less likely to elicit dysphoric responses.
Viewing neuroleptic dysphoria within a broader spectrum of disorders of subjective tolerability and exploring its neurobiological mechanisms is relevant to addressing the nuances of antipsychotic therapy, and could help unravel the questions surrounding the pathophysiology of depression, substance abuse and other dysphoric clinical states.
抗精神病药物所致烦躁不安(ND)是一种细微且未得到充分认识的副作用。它是一个综合性描述短语,涵盖了抗精神病药物引起的各种在觉醒、情绪、思维和动机方面令人不适的主观变化。了解这一现象具有广泛的临床和研究意义。
本综述根据神经影像学研究的最新发现、第二代抗精神病药物的累积经验以及诸如愉悦反应性、享乐调节和主观耐受性等新概念,审视了抗精神病药物时代原始研究中所确定的主题。
综述了涉及精神分裂症、图雷特氏症和口吃患者的临床人群使用抗精神病药物的实证研究、对正常健康志愿者进行的研究以及在动物身上进行的选定实验研究。
烦躁不安反应在治疗早期出现,通常表现为对药物的厌恶(药物厌恶性)。随着时间推移持续存在的烦躁不安可能导致不良临床后果,如治疗依从性差、药物滥用、临床结局不佳、自杀倾向增加以及生活质量受损。抗精神病药物因其在前额叶皮质和伏隔核壳中的多巴胺能阻断作用而干扰享乐能力的生理过程,这是烦躁不安反应发生的潜在中介机制。具有非典型受体阻断特征的第二代抗精神病药物引发烦躁不安反应的可能性较小。
在更广泛的主观耐受性障碍范围内看待抗精神病药物所致烦躁不安,并探索其神经生物学机制,对于解决抗精神病治疗的细微差别具有重要意义,并且有助于阐明围绕抑郁症、药物滥用和其他烦躁不安临床状态的病理生理学问题。